The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
163 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $13,824,211 in first-year total cost, median $79,250.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-A (J1)]10
- Special Emphasis Panel[ZCA1 SRB-1 (J1)]9
- Special Emphasis Panel[ZCA1 TCRB-V (J1)]9
- Special Emphasis Panel[ZCA1 RTRB-B (M2)]7
- Special Emphasis Panel[ZCA1 SRB-1 (O1)]7
Most frequent institutions
- OHIO STATE UNIVERSITY8
- UNIVERSITY OF TX MD ANDERSON CAN CTR6
- BAYLOR COLLEGE OF MEDICINE5
- SLOAN-KETTERING INST CAN RESEARCH5
- UNIVERSITY OF FLORIDA5
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Innate Immune Signaling in Fibrolamellar Carcinoma1R03CA270278-01A1 | HANSEN, STEEN HENNING | BOSTON CHILDREN'S HOSPITAL, MA | $177,000 | ZCA1 |
| 2023 | Health-related quality of life and patient reported outcomes among people living with HIV and cancer1R03CA278603-01A1 | ISLAM, JESSICA YASMINE | H. LEE MOFFITT CANCER CTR & RES INST, FL | $168,500 | ZCA1 |
| 2023 | Cancer Emulation Analysis with Deep Neural Network1R03CA276790-01A1 | MA, SHUANGGE | YALE UNIVERSITY, CT | $167,500 | ZCA1 |
| 2023 | Tumor downstaging with small molecule therapeutics to enhance Uveal Melanoma metastasis eradication by B7-H3 CAR T cells1R03CA280302-01 | FERRONE, CRISTINA R. | CEDARS-SINAI MEDICAL CENTER, CA | $167,000 | ZCA1 |
| 2023 | The Development and Psychometric Evaluation of the SIRS: A Social Isolation Risk Scale for Survivors of Head and Neck Cancer1R03CA273478-01A1 | MARZILIANO, ALLISON | FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, NY | $156,616 | ZCA1 |
| 2023 | Define the oncogenic role of Plk1 during hepatocellular carcinoma development using a genetically modified mouse model1R03CA283221-01 | FU, ZHENG | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $155,250 | ZCA1 |
| 2023 | Development of an Anti-Cancer Approach Through a Novel Pathway of Translational Regulation1R03CA277115-01A1 | KARAMYSHEV, ANDREY L | TEXAS TECH UNIVERSITY HEALTH SCIS CENTER, TX | $153,000 | ZCA1 |
| 2023 | Role of protein kinase ADCK5 in ovarian cancer1R03CA282712-01 | PADMANABHAN, ACHUTH | UNIVERSITY OF MARYLAND BALTIMORE COUNTY, MD | $150,271 | ZCA1 |
| 2023 | Ovarian cancer risk stratification using circulating miRNAs to assess BRCAness1R03CA283252-01 | ELIAS, KEVIN | BRIGHAM AND WOMEN'S HOSPITAL, MA | $116,323 | ZCA1 |
| 2023 | Menthol cigarette smoking-related blood metabolites and lung cancer risk1R03CA273625-01A1 | CAI, QIUYINYOON, HYUNG-SUK | UNIVERSITY OF FLORIDA, FL | $98,637 | ZCA1 |
| 2023 | Role of the Parkinson's susceptibility gene LRRK2 in NFAT-mediated malignant mesothelioma tumorigenesis1R03CA280410-01 | TESTA, JOSEPH R. | RESEARCH INST OF FOX CHASE CAN CTR, PA | $94,000 | ZCA1 |
| 2023 | Effects of Exercise on Changes in Cardiovascular Biomarkers in Patients with Breast Cancer During Anthracycline-based Chemotherapy1R03CA277194-01 | YU, ANTHONY FRANCIS | SLOAN-KETTERING INST CAN RESEARCH, NY | $88,500 | ZCA1 |
| 2023 | The role of ceramide kinase in metastasis growth from aggressive breast cancer1R03CA280307-01 | HAIT, NITAI | ROSWELL PARK CANCER INSTITUTE CORP, NY | $86,750 | ZCA1 |
| 2023 | Targeting the HMGB1-TLR5 pathway to prevent senescence-induced metastasis in breast cancer.1R03CA269552-01A1 | DAVID, GREGORY | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $84,750 | ZCA1 |
| 2023 | The role of NAGK cysteine deprotonation in nutrient stress and cancer progression1R03CA280299-01 | BLENIS, JOHN | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $84,750 | ZCA1 |
| 2023 | A Pilot Feasibility Study of an Intervention to Decrease Overtreatment of Low-risk Thyroid Cancer1R03CA283105-01 | PITT, SUSAN C | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $84,023 | ZCA1 |
| 2023 | Mapping of choline uptake and metabolism in brain tumors with deuterium metabolic imaging (DMI)1R03CA267438-01A1 | DE FEYTER, HENK | YALE UNIVERSITY, CT | $83,750 | ZCA1 |
| 2023 | Biology of terminal R-loops in splicing factor mutant cancers1R03CA270656-01A1 | PILLAI, MANOJ M. | YALE UNIVERSITY, CT | $83,750 | ZCA1 |
| 2023 | Wnt/beta-catenin signaling in early-onset colorectal cancer1R03CA279861-01 | YOCHUM, GREGORY S. | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $83,000 | ZCA1 |
| 2023 | Investigating the Ability of Human Blood Neutrophils to Kill Cancer1R03CA280714-01 | REICHNER, JONATHAN S | RHODE ISLAND HOSPITAL, RI | $82,000 | ZCA1 |
| 2023 | Post-translational modifications control JARID enzyme activity during DNA damage1R03CA273480-01A1 | MARTINEZ, ELISABETH D | UT SOUTHWESTERN MEDICAL CENTER, TX | $82,000 | ZCA1 |
| 2023 | Identify the target proteins of one ADC-specific and two SCC-specific pfeRNAs and investigate the mechanisms underlying the pfeRNA-protein interaction.1R03CA259658-01A1 | MEI, YUPING | JOHNS HOPKINS UNIVERSITY, MD | $81,875 | ZCA1 |
| 2023 | Disabled-2 in the metabolic regulation of oncopathways1R03CA277079-01 | KAIPPARETTU, BENNY ABRAHAMPARK, JUNHYOUNG | BAYLOR COLLEGE OF MEDICINE, TX | $80,000 | ZCA1 |
| 2023 | Spatial Profiling of Melanocytic Tumors and Their Microenvironment1R03CA277645-01A1 | KIURU, MAIJA HELENA TUULIA | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $80,000 | ZCA1 |
| 2023 | Statistical methods for breast cancer survival using the restricted mean survival time1R03CA267343-01A1 | LEE, CHI HYUN | UNIVERSITY OF MASSACHUSETTS AMHERST, MA | $79,750 | ZCA1 |
| 2023 | Examining the Impact of Medicaid's Prior Authorization Requirements for Tobacco Cessation Medications on Tobacco Cessation Medication Prescriptions1R03CA270451-01A1 | DILLENDER, MARCUS OWEN | VANDERBILT UNIVERSITY, TN | $79,250 | ZCA1 |
| 2023 | Investigation of STAT2 Signaling in the tumor microenvironment1R03CA273613-01A1 | GAMERO, ANA M | TEMPLE UNIV OF THE COMMONWEALTH, PA | $79,250 | ZCA1 |
| 2023 | Functions of a novel suppressor of oncogenic Ras1R03CA277213-01 | LI, WILLIS X | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $79,000 | ZCA1 |
| 2023 | Identification of enzymes inhibited by oncometabolites in Succinate Dehydrogenase mutant tumors1R03CA277217-01 | KIRSCHNER, LAWRENCE S | OHIO STATE UNIVERSITY, OH | $78,750 | ZCA1 |
| 2023 | Validation of OXPHOS gene amplification as a driver of hypoxia and treatment resistance in NSCLC1R03CA280489-01 | BENEJ, MARTIN | OHIO STATE UNIVERSITY, OH | $78,750 | ZCA1 |
| 2023 | The role of PRMT5 in preventing intra-chromosomal deletions in cancer cells1R03CA276967-01A1 | BOULEY, RENEEPETREACA, RUBEN CIPRIAN | OHIO STATE UNIVERSITY, OH | $78,750 | ZCA1 |
| 2023 | Pro-tumorigenic roles of a VHL isoform in Clear Cell Renal Cell Carcinoma1R03CA273598-01A1 | D'SOUZA-SCHOREY, CRISLYN | UNIVERSITY OF NOTRE DAME, IN | $78,250 | ZCA1 |
| 2023 | Mitostatin-evoked mitophagy for breast cancer inhibition1R03CA270830-01A1 | IOZZO, RENATO V. | THOMAS JEFFERSON UNIVERSITY, PA | $78,000 | ZCA1 |
| 2023 | Elucidating the relevance of BARD1-PLK1 interaction in PDAC and response to therapy1R03CA283232-01 | JAIN, ADITI | THOMAS JEFFERSON UNIVERSITY, PA | $78,000 | ZCA1 |
| 2023 | Claims-based measures of care coordination and long-term health among older women with endometrial cancer1R03CA267327-01A1 | NICHOLS, HAZEL B | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $77,750 | ZCA1 |
| 2023 | Improving the Safety and Quality of Eye Plaque Brachytherapy by Assembly with Intensity Modulated Loading1R03CA277236-01 | XING, LEI | STANFORD UNIVERSITY, CA | $77,462 | ZCA1 |
| 2023 | Probing INTS11 as a novel target in neuroblastoma1R03CA277050-01 | WAGNER, ERIC J | UNIVERSITY OF ROCHESTER, NY | $77,000 | ZCA1 |
| 2023 | Interventional method development for multiplexed personalized drug evaluation using implantable microdevices1R03CA270772-01A1 | BHAGAVATULA, SHARATH | BRIGHAM AND WOMEN'S HOSPITAL, MA | $76,860 | ZCA1 |
| 2023 | Targeting CXCL10 Chemokine Signaling in Breast Cancer Metastasis1R03CA270486-01A1 | KIM, SUWON | UNIVERSITY OF ARIZONA, AZ | $76,750 | ZCA1 |
| 2023 | Development of a Mouse Model to Study Targeted Therapy to Prevent CNS Invasion by Pediatric T-ALL1R03CA270815-01A1 | VINES, CHARLOTTE M | UNIVERSITY OF TEXAS EL PASO, TX | $76,750 | ZCA1 |
| 2023 | siRNA-based Gold Nanoparticles as a Therapeutic Enhancer for Triple Negative Breast Cancer (TNBC) Radiotherapy1R03CA277216-01A1 | JANIC, BRANISLAVA | HENRY FORD HEALTH SYSTEM, MI | $76,225 | ZCA1 |
| 2023 | To study the molecular oncogenesis of congenital Neurocutaneous melanocytosis in a preclinical transgenic mouse model1R03CA280130-01 | BASU, DIPANJAN | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $75,075 | ZCA1 |
| 2023 | Exploring the Use of a Web-Based Program for Older Adults Receiving Oral Anticancer Agents to Improve Communication and Self-Management1R03CA262908-01A1 | MARSHALL, VICTORIA KATE | UNIVERSITY OF SOUTH FLORIDA, FL | $74,750 | ZCA1 |
| 2023 | Mechanism of APE2 in genome integrity1R03CA270663-01A1 | YAN, SHAN | UNIVERSITY OF NORTH CAROLINA CHARLOTTE, NC | $74,333 | ZCA1 |
| 2023 | Metabolites regulating macrophage function in colorectal cancer1R03CA282844-01 | SUBRAMANIAN, SUBBAYA | UNIVERSITY OF MINNESOTA, MN | $74,274 | ZCA1 |
| 2023 | Exposing the role of MYC in small cell carcinoma of the ovary hypercalcemic type1R03CA273609-01A1 | WEISSMILLER, APRIL M. | MIDDLE TENNESSEE STATE UNIVERSITY, TN | $65,650 | ZCA1 |
| 2023 | An actionable secretory program that drives tumor progression in a genetically defined subset of lung squamous carcinoma1R03CA280382-01 | TAN, XIAOCHAO | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $59,253 | ZCA1 |
| 2023 | Developing a Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening among Rural Screening Age-Eligible Adults1R03CA270837-01A1 | MILLER, CARRIE A. | UNIVERSITY OF FLORIDA, FL | $2,993 | ZCA1 |
| 2022 | Recording the natural history of cancer progression using a Crainbow model of HER2+ cancer1R03CA270679-01 | BRAVO-CORDERO, JOSE JAVIER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $99,796 | ZCA1 |
| 2022 | A framework to integrate live-cell imaging with single-cell sequencing and learn how cells adapt to new environments1R03CA259873-01A1 | ANDOR, NOEMIHEISER, LAURA MADELINE | H. LEE MOFFITT CANCER CTR & RES INST, FL | $97,793 | ZCA1 |
| 2022 | Delineation of the Role of CAMKK2 in Bone-metastatic Prostate Cancer and its Therapeutic Implications1R03CA270450-01 | FRIGO, DANIEL EDWARD | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $95,765 | ZCA1 |
| 2022 | Pancreatic adenocarcinoma secretome as a dynamic biomarker for patient stromal reprogramming efficacy1R03CA273479-01 | CAMPBELL, PAUL MICHAEL | RESEARCH INST OF FOX CHASE CAN CTR, PA | $94,000 | ZCA1 |
| 2022 | Determinants of Repeat Colorectal Cancer Screening in a Safety-Net System1R03CA267445-01 | NONZEE, NARISSA JENNIFER | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $90,291 | ZCA1 |
| 2022 | Using biomarkers to elucidate the breastfeeding and ovarian cancer risk association1R03CA259659-01A1 | SASAMOTO, NAOKO | BRIGHAM AND WOMEN'S HOSPITAL, MA | $89,500 | ZCA1 |
| 2022 | Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)1R03CA262839-01A1 | GLIMCHER, LAURIE HOLLIS | DANA-FARBER CANCER INST, MA | $89,000 | ZCA1 |
| 2022 | Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer: A Prospective Study1R03CA259648-01A1 | BARRIO, ANDREA | SLOAN-KETTERING INST CAN RESEARCH, NY | $88,500 | ZCA1 |
| 2022 | Impact of germline mutations on the development of breast-implant associated anaplastic large cell lymphoma (BIA-ALCL) in women with textured breast implants1R03CA267435-01A1 | GHIONE, PAOLA | SLOAN-KETTERING INST CAN RESEARCH, NY | $88,500 | ZCA1 |
| 2022 | Pathway to Equity: Feasibility and Proof of Concept of Meaning-Centered Psychotherapy for Chinese Patients with Advanced Cancer1R03CA267333-01A1 | LUI, FLORENCE | SLOAN-KETTERING INST CAN RESEARCH, NY | $88,500 | ZCA1 |
| 2022 | The COACH Study: A Framework for individualized COaching in young Adult Cancer survivors to encourage Healthy behaviors1R03CA270475-01 | CROWDER, SYLVIA | H. LEE MOFFITT CANCER CTR & RES INST, FL | $86,855 | ZCA1 |
| 2022 | Understanding the impact of the Affordable Care Act on healthcare coverage, utilization, and outcomes for childhood cancer survivors1R03CA267456-01 | JI, XU | EMORY UNIVERSITY, GA | $85,989 | ZCA1 |
| 2022 | Delineating the Role of KAP1 in WNT-induced Colorectal Cancer1R03CA259672-01A1 | D'ORSO, IVAN | UT SOUTHWESTERN MEDICAL CENTER, TX | $82,000 | ZCA1 |
| 2022 | Delineating ARF negative regulation of PAF1C-dependent oncogenic programs1R03CA270685-01 | D'ORSO, IVAN | UT SOUTHWESTERN MEDICAL CENTER, TX | $82,000 | ZCA1 |
| 2022 | Statistical models for intratumor heterogeneity of tumor-infiltrated leukocytes in lung cancer1R03CA270725-01 | LI, ZIYI | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $81,000 | ZCA1 |
| 2022 | Characterizing the role of RNF25 in repair of DNA alkylation in blood cancers1R03CA256255-01A1 | TOCZYSKI, DAVID PAUL | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $80,750 | ZCA1 |
| 2022 | Health Behaviors and Mortality in Prostate Cancer Survivors in the Multiethnic Cohort Study1R03CA273486-01 | KENFIELD, STACEY | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $80,750 | ZCA1 |
| 2022 | Mechanisms of TGF-β-induced resistance to proteasome inhibitors in multiplemyeloma1R03CA259901-01A1 | KIM, BYUNG-GYU | CASE WESTERN RESERVE UNIVERSITY, OH | $80,500 | ZCA1 |
| 2022 | Development of a Precision Drug to target Y537S Mutant Estrogen Receptor in Metastatic Breast Cancer1R03CA259664-01A1 | PALANIAPPAN, MURUGESAN | BAYLOR COLLEGE OF MEDICINE, TX | $80,000 | ZCA1 |
| 2022 | Genome Instability induced in cancer cells carrying mutations in Type II topoisomerases1R03CA259884-01A1 | NITISS, JOHN L | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $79,950 | ZCA1 |
| 2022 | Role of Nod2 and AMP-kinase in obesity-associated liver cancer1R03CA273471-01 | GUPTA, DIPIKA | INDIANA UNIVERSITY INDIANAPOLIS, IN | $79,250 | ZCA1 |
| 2022 | Examine the function of APOBEC3B in epithelial ovarian cancer stem cells1R03CA270853-01 | JIANG, QINGFEI | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $79,000 | ZCA1 |
| 2022 | Evaluation of the antitumorigenic roles of miR-122 in pancreatic cancer1R03CA262490-01A1 | GOVINDARAJAN, RAJGOPAL | OHIO STATE UNIVERSITY, OH | $78,750 | ZCA1 |
| 2022 | Killing dormant tumor cells: the role of autopagy1R03CA256269-01A1 | SIMCOX, AMANDA | OHIO STATE UNIVERSITY, OH | $78,750 | ZCA1 |
| 2022 | Developing a Dyadic Survivorship Intervention for Black Women with Breast Cancer and Their Informal Caregivers1R03CA273485-01 | THOMPSON, TESS | WASHINGTON UNIVERSITY, MO | $78,750 | ZCA1 |
| 2022 | A novel strategy targeting TP63 for breast cancer prevention1R03CA259650-01A1 | SUH, NANJOO | RUTGERS, THE STATE UNIV OF N.J., NJ | $78,500 | ZCA1 |
| 2022 | New approaches to study tumor microvesicles1R03CA273469-01 | D'SOUZA-SCHOREY, CRISLYN | UNIVERSITY OF NOTRE DAME, IN | $78,250 | ZCA1 |
| 2022 | A pilot study to investigate in vivo Miro1 deletion in breast cancer tumorigenesis1R03CA270840-01 | CUNNIFF, BRIAN | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE, VT | $78,000 | ZCA1 |
| 2022 | Ecological Momentary Assessment of Quality of Life in Metastatic Breast Cancer1R03CA273489-01 | CONLEY, CLAIRE C | GEORGETOWN UNIVERSITY, DC | $78,000 | ZCA1 |
| 2022 | Impact of the COVID-19 pandemic on newly-diagnosed breast cancer1R03CA267469-01 | NYANTE, SARAH JANE | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $77,750 | ZCA1 |
| 2022 | A novel role of mutant p53 in intronic polyadenylation and impairment of DNA repair1R03CA256100-01A1 | LIU, LIANGZHANG, WEI | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $77,500 | ZCA1 |
| 2022 | Carcinogenic tobacco-specific nitrosamines induction of apurinic/apyrimidinic sites in DNA of human oral cells1R03CA259652-01A1 | GUO, JIEHONG | UNIVERSITY OF MINNESOTA, MN | $77,500 | ZCA1 |
| 2022 | Development of a Novel Method for the Identification and Characterization of Intercellular Communication in the Cancer Niche1R03CA269701-01 | GORDON, PETER M | UNIVERSITY OF MINNESOTA, MN | $77,500 | ZCA1 |
| 2022 | Biology of major folate transporters and STING signaling in cancer1R03CA259883-01A1 | HOU, ZHANJUN | WAYNE STATE UNIVERSITY, MI | $77,000 | ZCA1 |
| 2022 | SOX2-MYC Axis: Transcriptional Repression of the MYC Oncogene by SOX21R03CA267022-01A1 | RIZZINO, A. ANGIE | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $76,750 | ZCA1 |
| 2022 | "Post-translational modification of non-histone proteins as a mechanism of pMHC-I neo-ligand generation"1R03CA256718-01A1 | BRIGHT, ROBERT K | TEXAS TECH UNIVERSITY HEALTH SCIS CENTER, TX | $76,500 | ZCA1 |
| 2022 | Alterations in DNA Damage following Major Surgery and Hyperthermic Intraperitoneal Chemotherapy1R03CA267326-01A1 | KIM, JOSEPH | UNIVERSITY OF KENTUCKY, KY | $76,339 | ZCA1 |
| 2022 | SPDYE3, A Novel Cancer Testis (CT) Antigen for Glioma Immunotherapy1R03CA255820-01A1 | HUANG, JIANPING | UNIVERSITY OF FLORIDA, FL | $76,250 | ZCA1 |
| 2022 | Global metabolomics profiling, dietary factors, and colorectal cancer risk in the NIH-Consortium of Metabolomics Studies (COMETS)1R03CA270473-01 | OSE, JENNIFER | UNIVERSITY OF UTAH, UT | $76,250 | ZCA1 |
| 2022 | A Novel BRCA1 Heterozygosity Driven Breast Cancer Mouse Model to Identify Tumor Initiating Events and Therapeutic Strategies1R03CA270831-01 | PATHANIA, SHAILJA | UNIVERSITY OF MASSACHUSETTS BOSTON, MA | $76,250 | ZCA1 |
| 2022 | Quantifying NNK metabolites to facilitate Kava lung cancer prevention clinical translation1R03CA273467-01 | XING, CHENGGUO | UNIVERSITY OF FLORIDA, FL | $76,250 | ZCA1 |
| 2022 | S.E.N.D.: Developing a web-based, interactive guide to enhance patient-clinician electronic communication by focusing on specificity, expressing concerns, need, and directness1R03CA273617-01 | BYLUND, CARMA L. | UNIVERSITY OF FLORIDA, FL | $76,250 | ZCA1 |
| 2022 | Elucidation of New Phosphorylation Site of the EWS/ATF1 Fusion Oncoprotein in Clear Cell Sarcoma1R03CA262935-01A1 | TSUJI, YOSHIAKI | NORTH CAROLINA STATE UNIVERSITY RALEIGH, NC | $76,000 | ZCA1 |
| 2022 | Evaluate the Role and Mechanism of GPR4 in Immunotherapy-Related Colitis1R03CA249473-01A1 | YANG, LI | EAST CAROLINA UNIVERSITY, NC | $75,500 | ZCA1 |
| 2022 | A novel data-driven approach for personalizing smoking cessation pharmacotherapy1R03CA270677-01 | TOMKO, RACHEL LYNNWOLF, BETHANY JACOBS | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $75,437 | ZCA1 |
| 2022 | Combination Of Autophagy Selective Therapeutics (COAST) in Serous Ovarian Cancer1R03CA256104-01A1 | DELANEY, JOE R | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $75,354 | ZCA1 |
| 2022 | Targeting Lung Tissue Resident NK Cells with Inhaled IL-15 and TIGIT Blockade in Osteosarcoma1R03CA270854-01 | CANTER, ROBERT J. | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $75,304 | ZCA1 |
| 2022 | Communicating Cancer Risk of Alcohol: Impact of Narrative Pictorial Warning Labels1R03CA273391-01 | MA, ZEXIN | OAKLAND UNIVERSITY, MI | $75,000 | ZCA1 |
| 2022 | A multi-component non-pharmacological intervention to improve cognitive outcomes in hematologic cancer survivors1R03CA270671-01 | SHARAFELDIN, NOHA | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $74,250 | ZCA1 |
| 2022 | A novel strategy to debilitate breast cancer metastasis1R03CA267216-01A1 | SAMANT, RAJEEV S | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $74,250 | ZCA1 |
| 2022 | Bayesian Data Augmentation for Recurrent Events in Electronic Medical Records of Patients with Cancer1R03CA270478-01 | SCHNELL, PATRICK M | OHIO STATE UNIVERSITY, OH | $74,034 | ZCA1 |
| 2022 | Using photopolymerizable collagen matrices to investigate how progressive stiffening alters lymphatic trafficking of cancer and immune cells in pancreatic ductal adenocarcinoma1R03CA267449-01 | WHITTINGTON, CATHERINE F | WORCESTER POLYTECHNIC INSTITUTE, MA | $73,677 | ZCA1 |
| 2022 | Role of necroptosis in inflammation and NAFLD to HCC progression1R03CA262044-01A1 | SATHYASEELAN, DEEPA | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $72,500 | ZCA1 |
| 2022 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial1R03CA255992-01A1 | MANSOURI, ALIREZA | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $70,423 | ZCA1 |
| 2022 | Maternal acetaminophen use and childhood cancer1R03CA273608-01 | HECK, JULIA | UNIVERSITY OF NORTH TEXAS, TX | $70,086 | ZCA1 |
| 2022 | Leveraging tissue-specific regulatory maps and network-assisted analysis to identify novel genetic risk loci for esophageal adenocarcinoma1R03CA262845-01A1 | BUAS, MATTHEW FRANKYAN, LI | ROSWELL PARK CANCER INSTITUTE CORP, NY | $26,350 | ZCA1 |
| 2022 | Type II diabetes, related biomarkers and medications, and ovarian cancer risk1R03CA267113-01 | HARRIS, HOLLY RUTH | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $1 | ZCA1 |
| 2022 | Development and Validation of a Patient-Reported Measure Assessing Chimeric Antigen Receptor (CAR) T-Cell Therapy-Related Side Effects1R03CA259489-01A1 | BARATA, ANNA | H. LEE MOFFITT CANCER CTR & RES INST, FL | $1 | ZCA1 |
| 2021 | The role of chromatin remodeling factors in DNA double strand break repair1R03CA252498-01A1 | BOULEY, RENEEPETREACA, RUBEN CIPRIANYODER, RYAN J. | OHIO STATE UNIVERSITY, OH | $170,000 | ZCA1 |
| 2021 | Targeting differential kinase domain dimerization of EGFR mutants1R03CA259881-01 | TSUTSUI, YUKO | YALE UNIVERSITY, CT | $167,500 | ZCA1 |
| 2021 | B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC)1R03CA249542-01A1 | FERRONE, CRISTINA R.FERRONE, SOLDANO | MASSACHUSETTS GENERAL HOSPITAL, MA | $167,163 | ZCA1 |
| 2021 | Simultaneous targeting of tumor cells and tumor associated macrophages by RNA nanovector1R03CA252770-01A1 | LEE, TAE JIN | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $156,000 | ZCA1 |
| 2021 | Targeting Checkpoint Inhibition in Anti-Tumor Responses1R03CA252144-01A1 | BRADLEY, LINDA MAC PHERSON | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $97,500 | ZCA1 |
| 2021 | SibACCESS: Developing a Telehealth Intervention to Address Unmet Psychosocial Needs of Siblings of Children with Cancer1R03CA259898-01 | LONG, KRISTIN ANN | BOSTON UNIVERSITY (CHARLES RIVER CAMPUS), MA | $95,593 | ZCA1 |
| 2021 | Comprehensive identification of RAS mutations and allelic co-segregation patterns in colorectal cancer1R03CA256234-01 | SEREBRIISKII, ILYA | RESEARCH INST OF FOX CHASE CAN CTR, PA | $93,500 | ZCA1 |
| 2021 | Identification of first-in-class epigenetic inhibitors that target Thymine DNA Glycosylase (TDG) for future precision therapy of metastatic melanoma1R03CA256762-01 | BELLACOSA, ALFONSOYEN, TIMOTHY | RESEARCH INST OF FOX CHASE CAN CTR, PA | $93,500 | ZCA1 |
| 2021 | Using Connectomics and Machine Learning to Predict Survival in Diffuse Glioma1R03CA241862-01A1 | KESLER, SHELLI R | UNIVERSITY OF TEXAS AT AUSTIN, TX | $93,081 | ZCA1 |
| 2021 | A new mouse model for testing splice-switching therapies in IGF-driven cancers1R03CA259865-01 | CHANDLER, DAWN S | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $91,010 | ZCA1 |
| 2021 | Improving Mammography Completion and Follow-Up in Community Health Centers1R03CA256233-01 | EMMONS, KAREN M. | HARVARD SCHOOL OF PUBLIC HEALTH, MA | $90,057 | ZCA1 |
| 2021 | Early investigation of the role of desmoplastic fibrosis in cutaneous squamous cell carcinoma1R03CA252817-01A1 | SCHMULTS, CHRYSALYNE DELLING | BRIGHAM AND WOMEN'S HOSPITAL, MA | $89,500 | ZCA1 |
| 2021 | A Preventive Care Approach to Mitigate the Impact of Pediatric ALL Treatment on Sleep1R03CA259894-01 | BONA, KIRA O.ZHOU, ERIC S | DANA-FARBER CANCER INST, MA | $89,000 | ZCA1 |
| 2021 | Quantitative Analyses of HER2 Upregulation in Luminal Breast Cancer in Response to Neoadjuvant Endocrine Therapy1R03CA259594-01 | CHAUDHARY, LUBNA N.RUI, HALLGEIR | MEDICAL COLLEGE OF WISCONSIN, WI | $88,778 | ZCA1 |
| 2021 | Understanding the Guideline-Discordant Use of Bone Modifying Agents in Prostate Cancer1R03CA259863-01 | MITCHELL, AARON P | SLOAN-KETTERING INST CAN RESEARCH, NY | $88,500 | ZCA1 |
| 2021 | Understanding the impact of the Affordable Care Act on cancer treatment and outcomes for adolescents and young adults (AYA)1R03CA259665-01 | CASTELLINO, SHARON MARIEJI, XU | EMORY UNIVERSITY, GA | $85,823 | ZCA1 |
| 2021 | Rational design of drug combinations to target chemotherapy resistance in high-grade serous ovarian cancer via metabolomic profiling of patient-derived organoids1R03CA252674-01A1 | KRUMSIEK, JAN | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $84,750 | ZCA1 |
| 2021 | Immune Regulation of Disseminated Cancer Cell Dormancy1R03CA259656-01 | AGUIRRE-GHISO, JULIO A. | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $84,709 | ZCA1 |
| 2021 | Examining the impact of endogenous CD28 signaling on CAR T cells1R03CA256122-01 | OLEJNICZAK, SCOTT HENRY | ROSWELL PARK CANCER INSTITUTE CORP, NY | $84,100 | ZCA1 |
| 2021 | Novel 7SK non-coding RNA fusions in soft tissue sarcomas to tumorigenesis1R03CA246001-01A1 | OHM, JOYCE ELLENOLEJNICZAK, SCOTT HENRY | ROSWELL PARK CANCER INSTITUTE CORP, NY | $84,100 | ZCA1 |
| 2021 | New Statistical Methods for Cox Regression with Measurement Errors in Cancer and Nutritional Epidemiology1R03CA252808-01A1 | ZHOU, XIN | YALE UNIVERSITY, CT | $83,750 | ZCA1 |
| 2021 | Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC1R03CA256764-01A1 | DUDA, DAN GABRIELFERRONE, SOLDANO | MASSACHUSETTS GENERAL HOSPITAL, MA | $83,660 | ZCA1 |
| 2021 | Treatment of parathyroid neoplasia by pharmacologic cdk4/6 inhibition1R03CA259649-01 | COSTA, JESSICA | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $82,000 | ZCA1 |
| 2021 | Testing in-situ formed nanofibers for inhibiting metastatic osteosarcoma (mOS) in murine models1R03CA262920-01 | XU, BING | BRANDEIS UNIVERSITY, MA | $81,250 | ZCA1 |
| 2021 | Modeling Esophageal Squamous Cell Cancer Initiation1R03CA256207-01 | PARK, JAE-IL | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $81,000 | ZCA1 |
| 2021 | Impact of diagnostic peritoneal lavage on omentum metastasis1R03CA255193-01A1 | NAORA, HONAMI | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $81,000 | ZCA1 |
| 2021 | Minimizing the risk of therapy-related myeloid neoplasms by inhibiting genotoxic stress-induced expansion of leukemia-initiating cells with p53 mutations1R03CA249562-01A1 | LEE, CHANG-LUNG | DUKE UNIVERSITY, NC | $80,500 | ZCA1 |
| 2021 | Defining the role of FAM83B in lung cancer using a new mouse model1R03CA259903-01 | JACKSON, MARK W. | CASE WESTERN RESERVE UNIVERSITY, OH | $80,500 | ZCA1 |
| 2021 | Genetic analysis of lung cancer susceptibility1R03CA256222-01 | AMOS, CHRISTOPHER I. | BAYLOR COLLEGE OF MEDICINE, TX | $80,000 | ZCA1 |
| 2021 | Dynamic BH3 Profiling with Patient Derived Organoids of Esophageal Cancer and Mesothelioma Enable Precision-Based Targeting of the Mitochondrial Apoptotic Pathway1R03CA252685-01A1 | RIPLEY, ROBERT TAYLOR | BAYLOR COLLEGE OF MEDICINE, TX | $80,000 | ZCA1 |
| 2021 | Evaluating Etiological Impact of Metatranscriptomic and Immunological Features for Lung Cancer1R03CA262911-01 | LIU, YANHONG | BAYLOR COLLEGE OF MEDICINE, TX | $80,000 | ZCA1 |
| 2021 | Optimizing the Biological Effectiveness of Intensity-Modulated Proton Therapy1R03CA256220-01 | CAO, WENHUA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $79,698 | ZCA1 |
| 2021 | 3D Ultra-sensitive Ultrasound Microvessel Imaging for Breast Mass Differentiation1R03CA241020-01A1 | GONG, PING | MAYO CLINIC ROCHESTER, MN | $79,500 | ZCA1 |
| 2021 | Increasing aerobic and muscle-strengthening physical activity in Latinas via interactive web-based technology1R03CA252500-01A1 | BENITEZ, TANYA J | BROWN UNIVERSITY, RI | $79,500 | ZCA1 |
| 2021 | Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and lung cancer prognosis1R03CA256238-01 | LUO, JUHUA | TRUSTEES OF INDIANA UNIVERSITY, IN | $79,250 | ZCA1 |
| 2021 | Nannocystin Reagents to Elucidate the Role of Elongation Factor 1a in Apoptosis1R03CA255970-01 | DIVER, STEVEN T | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $78,581 | ZCA1 |
| 2021 | Gene Expression Analysis of Dog Natural Killer Cells as Immunotherapy Target1R03CA252793-01A1 | CANTER, ROBERT J. | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $78,500 | ZCA1 |
| 2021 | TURNing RanBP9 on NSCLC1R03CA259389-01 | COPPOLA, VINCENZO | OHIO STATE UNIVERSITY, OH | $78,000 | ZCA1 |
| 2021 | A Simulation Modeling Study to Support Personalized Breast Cancer Prevention and Early Detection in High-Risk Women1R03CA259896-01 | JAYASEKERA, JINANI | GEORGETOWN UNIVERSITY, DC | $78,000 | ZCA1 |
| 2021 | Lung epithelial lineage-specific factors in the control of immune system evasion genes in tumor cells1R03CA252779-01A1 | RAMIREZ, MARIA ISABEL | THOMAS JEFFERSON UNIVERSITY, PA | $78,000 | ZCA1 |
| 2021 | Pathogenetic roles of USO1 in leukemogenesis1R03CA251845-01A1 | RAO, DINESH S | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $78,000 | ZCA1 |
| 2021 | The malignant microenvironment in early cutaneous T-cell lymphoma1R03CA252818-01A1 | NIKBAKHT, NEDA | THOMAS JEFFERSON UNIVERSITY, PA | $78,000 | ZCA1 |
| 2021 | Targeting histone methyltransferases EHMT1 and EHMT2 to sensitize PARP inhibitor-resistant ovarian cancer1R03CA249571-01A1 | WATSON, ZACHARY LEVI | UNIVERSITY OF COLORADO DENVER, CO | $77,750 | ZCA1 |
| 2021 | The mechanism of gp78 ubiquitin ligase in suppressing hepatocellular carcinoma1R03CA249484-01A1 | XIE, YOUMING | WAYNE STATE UNIVERSITY, MI | $77,000 | ZCA1 |
| 2021 | Co-Oncogenic Role of ECD in HER2-Driven Breast Cancer1R03CA253193-01A1 | BAND, VIMLA | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $76,542 | ZCA1 |
| 2021 | Fatty acid synthase in regulation of UDP-GlcNAc synthesis in colorectal cancer1R03CA262720-01 | ZAYTSEVA, YEKATERINA | UNIVERSITY OF KENTUCKY, KY | $76,500 | ZCA1 |
| 2021 | E2F family transcription factors are directly regulated by TRIM28 to promote castration-resistance in prostate cancer1R03CA256230-01A1 | FONG, KA-WING | UNIVERSITY OF KENTUCKY, KY | $76,500 | ZCA1 |
| 2021 | Identifying the role of short-term fine particulate matter air pollution in the heart and lung health outcomes of adolescent and young adult cancer survivors1R03CA256263-01 | KIRCHHOFF, ANNE C | UNIVERSITY OF UTAH, UT | $76,250 | ZCA1 |
| 2021 | Mechanisms of protein degradation that control signal transduction by Ras-Raf-MEK-ERK1R03CA248684-01A1 | DE LA COVA, CLAIRE | UNIVERSITY OF WISCONSIN MILWAUKEE, WI | $76,000 | ZCA1 |
| 2021 | Colorectal tumorigenesis on a cricket powder-based diet versus diets based on more typical protein sources1R03CA252672-01A1 | MASON, JOEL B | TUFTS UNIVERSITY BOSTON, MA | $75,500 | ZCA1 |
| 2021 | Statistical methods for cancer progression delineation and subtype identification1R03CA259670-01 | WANG, CHI | UNIVERSITY OF KENTUCKY, KY | $74,902 | ZCA1 |
| 2021 | Genetic code expansion to enable the development of short, diverse peptide libraries1R03CA259876-01 | HARTMAN, MATTHEW C | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $74,863 | ZCA1 |
| 2021 | Accurate DCE-MRI Measurement of Glioblastoma using Point-of-care Portable Perfusion Phantom1R03CA245986-01A1 | KIM, HARRISON | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $74,250 | ZCA1 |
| 2021 | Chemoprevention of lung cancer with the β-blocker carvedilol1R03CA256241-01 | HUANG, YING | WESTERN UNIVERSITY OF HEALTH SCIENCES, CA | $70,500 | ZCA1 |
| 2021 | Evaluating How Fluid Shear Stress Alters Estrogen Receptor Phenotype in Metastatic Breast Cancer1R03CA262944-01 | MARTIN, ELIZABETH | LOUISIANA STATE UNIV A&M COL BATON ROUGE, LA | $70,136 | ZCA1 |
| 2021 | A New Strategy to Increase Proteotoxic Cell Death in Hepatocellular Carcinoma1R03CA245780-01A1 | PEREZ-STABLE, CARLOS M | SOUTH FLORIDA VA FDN/RESEARCH/ EDUCATION, FL | $63,600 | ZCA1 |
| 2021 | Targeted therapy against TERT oncogene-rearranged neuroblastoma1R03CA251976-01A1 | LIU, TAOMARSHALL, GLENN M | UNIVERSITY OF NEW SOUTH WALES | $54,000 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.